Achaogen Initiates C-Scape Clinical Development Program with Phase 1 Study of Orally-Administered Antibacterial Candidate

SOUTH SAN FRANCISCO, Calif., June 01, 2017 (GLOBE NEWSWIRE) — Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it has dosed the first patient with C-Scape in a Phase 1 clinical pharmacology, dosing and safety study. C-Scape, a combination of an approved beta-lactam and an approved beta-lactamase inhibitor, is the Company’s second antibacterial candidate being developed for MDR gram-negative infections.